Fig. 3
CHCHD4 expression links growth rate to CI activity and mTORC1 signalling in tumour cells. a Chart shows the growth rates of a panel of tumour cell lines over 72 h. ± SD. n = 3. b Chart shows growth of tumour cell lines described in (a) treated with 100 nM rotenone for 72 h, relative to untreated (0 nM) cells. ± SD. n = 3. c Chart shows xy scatter of the fold change in growth of indicated tumour cell lines at 72 h vs 0h, compared to their relative growth rate when treated with 100 nM rotenone. Trend line (dashed blue) and R2 value (Spearman’s correlation) shown. d Chart shows relative abundance of CHCHD4 transcripts measured by QPCR in HCT116 and U2OS cells. CHCHD4 expression is relative to ACTB and normalised to CHCHD4 transcript levels in HCT116 cells. ± SD. n = 3. e Western blots show levels of CHCHD4, NDUFB10 (CI), SDHA (CII) UQCRC2 (CIII), COXIV (CIV) in whole cell lysates of HCT116 and U2OS cells. β-Actin was used as a load control. f Chart shows basal OCR of HCT116 and U2OS cells, measured by Seahorse respirometry. ± SD. n = 3. g Western blots show levels of phosphorylated (P-) and total (T-) p70S6K, puromycin labelled polypeptides in HCT116 and U2OS cells treated as indicated for 24 h. β-Actin was used as a load control. Relative band intensities of P-p70S6K indicated